Product Information
RASUVO 7.5 MG/0.15 ML AUTOINJ is a brand product labeled by Medexus Pharma Inc., priced at $960.2932 per ML under NDC 59137050504. Its NADAC has been published 81 times since Mar 19, 2025.
FDA first approved this application on Jul 10, 2014.
The High Outlier badge above means this manufacturer's average price in the methotrexate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
7.5 mg/.15mL
Manufacturer
Medexus Pharma Inc.NDC
59137050504
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
4/1/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA205776FDA Approved
7/10/2014
On Market Since
7/10/2014
Pharmacological Classes
Price Statistics
The NADAC for RASUVO 7.5 MG/0.15 ML AUTOINJ has been published 81 times since Mar 19, 2025, and over the history we have for it it has risen 5.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $960.2932 per ML |
|---|---|
| All-time high | $960.2932 (Sep 30, 2026) |
| All-time low | $908.7333 (Mar 19, 2025) |
| 52-week high | $960.2932 |
| 52-week low | $936.1226 |
| Median price | $936.1226 |
| Average price | $943.5032 |
| Largest weekly change | +3.0% (Apr 2, 2025) |
| Weeks tracked | 81 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the methotrexate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Medexus Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RASUVO 7.5 MG/0.15 ML AUTOINJ?
The current National Average Drug Acquisition Cost (NADAC) for RASUVO 7.5 MG/0.15 ML AUTOINJ, manufactured by Medexus Pharma Inc., is $960.2932 per ML (NDC 59137050504), effective Sep 30, 2026.
How has the price of RASUVO 7.5 MG/0.15 ML AUTOINJ changed over time?
Over the history we have for it, the NADAC for RASUVO 7.5 MG/0.15 ML AUTOINJ has risen 5.7%. It has been tracked across 81 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for RASUVO 7.5 MG/0.15 ML AUTOINJ?
Since Mar 19, 2025, the NADAC for RASUVO 7.5 MG/0.15 ML AUTOINJ has ranged from a low of $908.7333 (Mar 19, 2025) to a high of $960.2932 (Sep 30, 2026), with a median of $936.1226 per ML.
Are there cheaper alternatives to RASUVO 7.5 MG/0.15 ML AUTOINJ?
No other NADAC-published product currently shares the active ingredient and strength of RASUVO 7.5 MG/0.15 ML AUTOINJ in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RASUVO 7.5 MG/0.15 ML AUTOINJ?
RASUVO 7.5 MG/0.15 ML AUTOINJ (NDC 59137050504) is labeled by Medexus Pharma Inc., and CMS classifies it as a brand product.